Evidence map›Paper›PMID 42500124›Full record

ArticleOpen forum infectious diseases2026

Prevalence of Hepatitis B Coinfection in People With HIV by Birth-Year Cohort.

So Jeong Lee, Tarfa Verinumbe, Catherine R Lesko, Anthony Fojo, Joyce Jones, Jeanne Keruly, LaQuita N Snow, Richard D Moore, Mark Sulkowski, Oluwaseun Falade-Nwulia

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

So Jeong LeeDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.
Tarfa VerinumbeDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-1438-2698
Catherine R LeskoDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-1717-2592
Anthony FojoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Joyce JonesDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-5882-0907
Jeanne KerulyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
LaQuita N SnowDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Richard D MooreDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Mark SulkowskiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Oluwaseun Falade-NwuliaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-2321-2295

Funding

Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Ending the HIV Epidemic in Rural America (EHE-RA): Local Interventions, Co-Epidemics, and Social DeterminantsR01MD018539 · NIMHD · JOHNS HOPKINS UNIVERSITY · PI Anthony Todd Fojo · 2022 to 2026
$4.0M
Optimizing outcomes at the intersection of HIV and mental health: Prediction, precision medicine, and population healthK08MH118094 · NIMH · JOHNS HOPKINS UNIVERSITY · PI FOJO, ANTHONY TODD · 2018 to 2022
$953k
Unhealthy alcohol use, other drug use, and mental health disorders: comorbidity burden in people with HIV, gaps in treatment, and impact on the HIV care continuumK01AA028193 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI LESKO, CATHERINE · 2019 to 2023
$900k
NIAAA NIH HHS K01 AA028193NIDA NIH HHS U01 DA036935NIMHD NIH HHS R01 MD018539NIMH NIH HHS K08 MH118094
6 · The paper itself

Abstract

Background: Availability of the hepatitis B virus (HBV) vaccine in the United States since 1982 and recommendations for universal/catch-up vaccination of infants and children since the 1990s may be associated with lower HBV prevalence among people with human immunodeficiency virus (HIV; PWH) born after 1980. Methods: Active HBV infection prevalence, defined as the proportion of patients with a positive hepatitis B surface antigen result, was assessed among PWH at entry into a clinical cohort. Patients were categorized into birth-year cohorts of 1940-1959, 1960-1979, or 1980-1999 and then further dichotomized into pre- and post-1980 birth-year cohorts. Log binomial regression was used to assess the association of birth-year cohort with hepatitis B surface antigen positivity, adjusting for race/ethnicity, HIV infection risk factor, baseline HIV viral load and CD4 Results: Among 5598 PWH, most were male (67%) and Black (77%), with a mean age (SD) of 39.7 (9.6) years at cohort entry. Approximately a third of the participants (30%) identified as men who have sex with men, and 39% reported a history of injection drug use. At cohort entry, the majority had a CD4 Conclusions: PWH born after 1980 had a lower prevalence of HBV coinfection than those born before 1980, supporting the potential impact of universal childhood HBV vaccination.

Indexed as

Hepatitis Bpeople with HIVvaccination

Identifiers

PMID42500124
PMCPMC13397113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.